ABCB1/P-glycoprotein Expression Influence on Non-metastatic Osteosarcoma of the Extremities
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Osteosarcoma
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 12 years and 30 years
- Gender
- Both males and females
Description
The Primary objective is: - Disease-free survival measured as a 5-year rate in patients with localized osteosarcoma treated, according to standard practice, with all the drugs currently registered for the treatment of non-metastatic osteosarcoma (methotrexate, cisplatin, adriamycin, ifosfamide, MTP-...
The Primary objective is: - Disease-free survival measured as a 5-year rate in patients with localized osteosarcoma treated, according to standard practice, with all the drugs currently registered for the treatment of non-metastatic osteosarcoma (methotrexate, cisplatin, adriamycin, ifosfamide, MTP-PE), according to ABCB1 / P-glycoprotein expression. The Secondary objectives are: Evaluate overall survival in a homogeneous population of patients with non-metastatic osteosarcoma. Disease-free survival at 2 and 3 years.
Tracking Information
- NCT #
- NCT04383288
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Óscar Gallego, Dr. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Principal Investigator: Luis Gros, Dr. Hospital Vall d'Hebron
Get Well Soon